查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496019

全球藥用輔料市場：2024-2029 年預測

Global Pharmaceutical Excipients Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 126 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

藥用輔料市場預計將從2022年的69.17億美元增至2029年的128.22億美元，預測期內複合年成長率為9.23%。

賦形劑是藥理學上的休眠物質，與動態原料藥一起使用，可簡化藥物生產並有助於潤滑性、流動性、劣化和味道。它還具有抗菌作用並促進鎮靜劑的生理同化。製藥工業使用的賦形劑包括填充劑、粘合劑、油、香料、甜味劑、螯合劑、溶劑和助溶劑。為了提供物理和化學穩定的散裝劑量配方，藥廠嚴重依賴藥用輔料。

全球廣泛使用的藥物劑型包括錠劑、膠囊、外用乳膏劑和凝膠劑、植入、口服製劑、眼藥水、注射劑、吸入劑、經皮吸收貼片、含片、栓劑等。藥物賦形劑在這些藥物製劑中用於輔助加工、增加原料藥的體積和體積，並確保、支持和增加最終產品中劑型的穩定性。

癌症、急性呼吸道疾病、心臟病、糖尿病和其他慢性疾病是全球死亡率增加的主要促進因素。僅在美國，十分之六的人經常患有慢性疾病，需要持續定期服藥。根據國際糖尿病聯盟（IDF）的數據，2019年約有4.63億人（20-79歲的成年人）患有糖尿病，預計到2045年這一數字將增加至7億。

市場促進因素：

  • 不斷增加的研發（R＆D）預計將推動藥用輔料市場的發展。

隨著藥物配方研究的不斷深入和進步，多功能賦形劑被用來改善生產過程和藥物品質。賦形劑透過提高治療的依從性和可行性，在藥廠的持續強化中發揮關鍵作用。

製藥業對研發的日益關注預計將對藥用輔料產業產生重大影響。這些惰性物質可提高藥物穩定性和溶解度，並可用於藥物傳遞形式。它們影響生物有效性、排放曲線和動態藥物穩健性，並在藥物進步中發揮關鍵作用。先進的鴉片類藥物遞送框架（例如奈米顆粒和脂質體）通常需要專門的賦形劑。

FDA 和 EMA 等政府機構不斷升級藥品監管標準指南和基準，推動對輔料的需求以滿足最新措施。根據特定患者需求和恢復區域定製藥物配方非常重要。隨著製藥公司致力於全面的研究和開發，對藥用輔料的需求遍及世界各地，生產商看到未來幾年有更多的機會供應更廣泛的地區。

  • 慢性病的增加預計將推動藥用輔料市場的成長。

學名藥產業的成長是由慢性病的增加和輔料的改進所推動的，這是藥品市場成長的關鍵。心血管疾病、糖尿病、癌症和慢性呼吸道疾病等主要慢性疾病的增加刺激了對各種治療方案的需求。

製藥公司正在創造創新的藥物配方來滿足要求，以及新的給藥框架，以提高適用性和有效性，同時保持患者的舒適度和依從性。這些藥物通常涉及複雜的治療方案，並需要藥用輔料來提高藥物穩定性、控制藥物釋放速率並提高生物有效性。持續釋放、標靶遞送至特定組織以及克服溶解度和吸收問題需要專門的藥物遞送系統。

藥物賦形劑也用於製造患者友善的劑型，例如緩釋片和方便的口服製劑。個人化醫療和生技藥品等治療方法的創新通常需要專門的賦形劑來確保穩定性和有效性。旨在改善慢性病有效治療方法機會的政府措施和醫療保健政策可能會促進藥用輔料市場的成長。

市場限制因素：

  • 製造新輔料所需的成本和時間可能會阻礙市場成長。

藥用輔料需要在生產現場接受監管機構的強制測試。由於業界缺乏輔料核准和製造的具體指南，因此與輔料相關的研究和開發舉措迫在眉睫。如果新藥核准失敗，輔料也會失敗，即使與輔料無關。此外，賦形劑的製造非常耗時且成本高。

主要進展

  • 2023 年 10 月 - 路博潤生命科學健康公司以其創新技術 Apisolex™ 聚合物增溶賦形劑榮獲巴塞隆納 CPhI 成品配方獎。該獎項由 The Medicine Maker 認可，旨在表彰來自 12 個創新類別的 180 多個參賽作品中的突破性創新。 Apisolex(TM) 聚合物是基於聚（氨基酸）的賦形劑，是 20 多年來第一種腸胃外溶解度增強賦形劑，可將疏水性原料藥的溶解度提高高達 50,000 倍讓我來做。
  • 2023 年 10 月 - 科萊恩醫療保健在巴塞隆納 CPHI 上展示了一系列新的賦形劑，可提高原料藥配方的穩定性和溶解度。該公司正在推出三種新的 VitiPure® 賦形劑，可用於各種 API 配方和給藥途徑，包括 mRNA 疫苗和生物製藥等敏感配方。科萊恩醫療保健是一家輔料一站式解決方案提供商，為獨特的應用提供從標準到高純度等級的靈活配方。
  • 2023 年 10 月 - 羅蓋特在其濕敏藥物和營養原料食品產品組合中增加了三種新的輔料等級。這些等級，包括部分預膠化澱粉 Lycatab CT-LM、Microcel 103 SD 和 Microcel 113 SD，是具有獨特穩定和防潮效果的結晶纖維素。這些成分旨在幫助製藥商最佳化藥物輸送，無論製造方法或配方類型如何。羅蓋特的防潮特性包含一系列全面的低水分活度 (Aw) 賦形劑，以促進涉及對水分敏感的活性成分的應用中的有效藥物輸送。
  • 2022 年 7 月 - 全球製藥和食品賦形劑解決方案領導者 DFE Pharma 透過推出 Lactohale® 400 擴大了其乾粉吸入 (DPI) 產品組合。這種新等級可以客製化以滿足特定製藥公司的需求，並且是與負責人合作開發的，以確保患者獲得正確的結果。 DFE Pharma 全面的乳糖輔料產品組合旨在為市場上所有類型的吸入藥物提供合適的特性。 Lactohale(R) 400 是一種研磨的無水乳糖等級，適用於需要良好流動和絮凝性能的 DPI 應用。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章全球藥用輔料市場：依輔料類型

  • 介紹
  • 聚合物
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 酒精
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 醣類
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 礦物
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章全球藥用輔料市場：按製劑類型

  • 介紹
  • 口服
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 外用
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 胃腸外的
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章全球藥用輔料市場：依功能分類

  • 介紹
  • 被覆劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 調味劑/甜味劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 潤滑劑和潤滑劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 著色劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 乳化劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 緩衝劑
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章全球藥用輔料市場：依分銷管道分類

  • 介紹
  • 線上
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 離線
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第9章全球藥用輔料市場：按地區

  • 介紹
  • 北美洲
    • 按添加劑類型
    • 按處方類型
    • 按功能分類
    • 按分銷管道
    • 按國家/地區
  • 南美洲
    • 按添加劑類型
    • 按處方類型
    • 按功能分類
    • 按分銷管道
    • 按國家/地區
  • 歐洲
    • 按添加劑類型
    • 按處方類型
    • 按功能分類
    • 按分銷管道
    • 按國家/地區
  • 中東/非洲
    • 按添加劑類型
    • 按處方類型
    • 按功能分類
    • 按分銷管道
    • 按國家/地區
  • 亞太地區
    • 按添加劑類型
    • 按處方類型
    • 按功能分類
    • 按分銷管道
    • 按國家/地區

第10章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第11章 公司簡介

  • Ashland Global Holdings
  • DuPont
  • BASF SE
  • Roquette Feres
  • Evonik Industries AG
  • Croda International
  • Associated British Foods
  • Archer Daniels Midland Company
  • Lubrizol Corporation
簡介目錄
Product Code: KSI061611832

The global pharmaceutical excipients market is projected to witness a CAGR of 9.23% during the forecast period to reach a total market size of US$12.822 billion by 2029, increasing from US$6.917 billion in 2022.

Excipients are pharmacologically dormant substances included in conjunction with the dynamic medicate substance to streamline the production of the drug item and help in lubricity, flowability, deterioration, and taste. They may bestow a few shapes of antimicrobial work and additionally encourage the physiological assimilation of the sedate. A few of the excipients utilized in pharmaceutical industries include fillers, binders, oils, flavoring specialists, sweeteners, chelating operators, solvents, co-solvents, etc. To supply the bulk dose formulations steady in physical and chemical, the formulator is profoundly subordinate to the pharmaceutical excipients.

A few pharmaceutical dosage forms that are easily and widely available and utilized globally are tablets, capsules, topical creams and gels, implants, oral dosage, eye drops, injectable products, inhalers, transdermal patches, lozenges, and suppositories. Pharmaceutical excipients are utilized in these pharmaceutical medication formulations to help the processing, providing bulk or volume to API, and securing, supporting, or incrementing the stability of the dosage forms in the final product.

Cancer, acute respiratory disease, heart stroke, diabetes, and other chronic diseases are the major driving factors of rising mortality in the world. Inside the United States alone, six out of ten individuals endure chronic illness regularly and require persistent and regular pharmaceutical medicines regime intake. As per the International Diabetes Federation (IDF), around 463 million people (20-79 years adults) were living with diabetes in 2019, and by 2045, the number is expected to increase to 700 million, showing a rise in demand for medicines in turn boosting the Pharmaceutical Excipients market growth.

Market Drivers:

  • Increasing research and development (R&D) is expected to boost the pharmaceutical excipients market.

Expanded investigations and advancements in pharmaceutical formulations utilize multi-functional excipients to progress the process of production and medication quality. Excipients play a significant part in helping pharmaceutical manufacturers in giving progress persistent bolster by improving compliance and treatment viability.

The pharmaceutical industry's rising attention on R&D is anticipated to emphatically affect the industry for pharmaceutical excipients. These inert substances improve medicate steadiness and solvency and help in medicate delivery forms. They play a vital part in medication advancement, influencing the bioavailability, discharge profile, and solidness of dynamic drugs. R&D endeavors drive advancement in pharmaceutical medication details, with progressed sedate conveyance frameworks such as nanoparticles and liposomes frequently requiring specialized excipients.

Administrative bodies just like the FDA and EMA continuously upgrade regulations standard guidelines and benchmarks for pharmaceutical items, driving the requirement for excipients that meet the most recent measures. Customization of medication formulations on the basis of particular patient needs and restorative zones are significant. As pharmaceutical companies contribute to R&D all-inclusive, the request for pharmaceutical excipients is likely to extend around the world, with producers seeing expanded openings to supply to broader regions in the years ahead.

  • A rise in chronic diseases is expected to surge the pharmaceutical excipients market growth.

The rising generics medicine industry is driven by the rise in chronic illnesses and the improvement of excipients, which are a key figure within the pharmaceutical market growth. The rise in major chronic disorders, like cardiovascular, diabetes, cancer, and chronic respiratory conditions, is fueling the demand for different treatment alternatives.

Pharmaceutical companies are creating innovative medication formulations for fulfilling the requirement as well as emerging delivery frameworks to progress adequacy and effectiveness with the comfort and compliance of patients. These medicines frequently include complex regimens, requiring pharmaceutical excipients to improve the stability of the medicine, control release rates of the drug, and enhance its bioavailability. Specialized drug delivery systems are necessary for sustained release, targeted delivery to specific tissues, and overcoming solubility and absorption issues.

Pharmaceutical excipients can also be used to create patient-friendly dosage forms, such as extended-release tablets or convenient oral formulations. Innovations in therapeutic approaches, such as personalized medicine and biologics, often require specialized excipients for stability and effectiveness. Government initiatives and healthcare policies aimed at improving access to effective treatments for chronic diseases may contribute to the pharmaceutical excipient market growth.

Market Restraints:

  • Cost and time consumed in creating new excipients could hinder the market growth.

Pharmaceutical Excipients require mandatory inspections by the regulatory authorities of the manufacturing site. The industry lacks separate guidelines for approval and manufacturing of excipients is impending R&D initiatives related to excipients. If a new drug approval fails, the excipient also fails, even if it is not related to the excipient. Moreover, a considerable amount of time and cost goes into creating an excipient.

Key Developments:

  • October 2023- Lubrizol Life Science Health won the Finished Formulation Award at CPhI Barcelona for its innovative technology, Apisolex(TM) Polymer solubilizing excipient. The award, which was recognized by The Medicine Maker, was awarded to a breakthrough innovation among over 180 entries in 12 innovation categories. The winners were announced at a networking reception with over 500 attendees.Apisolex(TM) Polymer, a poly(amino acid)-based excipient, is the first solubility-enhancing excipient for parenteral use in over 20 years, enhancing hydrophobic API solubility by up to 50,000-fold.
  • October 2023- Clariant Health Care launched a new range of excipients at CPHI Barcelona to improve the stability and solubility of active pharmaceutical ingredient (API) formulations. The company will unveil three new VitiPure(R) excipients, which can be used for various API formulations and administration routes, including sensitive ones like mRNA vaccines and biological medications. Clariant Health Care is a one-stop shop solution provider of excipients, offering a range from standard to highly purified grades for unique application-specific formulation flexibility.
  • October 2023- Roquette added three new excipient grades for moisture-sensitive active pharmaceutical and nutraceutical ingredients to its portfolio. These grades, including partially pregelatinized starch Lycatab CT-LM, Microcel 103 SD, and Microcel 113 SD, are microcrystalline cellulose with unique stabilizing and moisture-protective benefits. These ingredients are designed to help pharmaceutical manufacturers optimize drug delivery, regardless of production method or formulation type. Roquette's moisture protection profile incorporated a comprehensive variety of low water activity (Aw) excipients, which bolster effective drug advancement in applications including moisture-sensitive active ingredients.
  • July 2022- DFE Pharma, a global leader in pharma- and nutraceutical excipient solutions, expanded its Dry Powder Inhalation (DPI) portfolio with the launch of Lactohale(R) 400. This new grade can be customized to meet specific pharmaceutical company needs and developed jointly with formulators to ensure the right outcomes for patients. DFE Pharma's comprehensive range of lactose-based excipients is designed to offer the right characteristics for the full variety of inhaled medicines in the market. Lactohale(R) 400 is a milled, anhydrous lactose grade suitable for DPI applications requiring good flow and cohesiveness.

Key Segmentation:

Global Pharmaceutical Excipients Market is segmented and analyzed as below:

By Excipient Type

  • Polymers
  • Alcohols
  • Sugars
  • Minerals
  • Others

By Formulation Type

  • Oral
  • Topical
  • Parenteral
  • Others

By Functionality

  • Coating Agents
  • Flavoring Agents & Sweeteners
  • Lubricants & Glidants
  • Colorants
  • Emulsifying Agents
  • Buffering Agents
  • Others

By Distribution Channel

  • Online
  • Offline

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • Australia
  • Japan
  • South Korea
  • India
  • Thailand
  • Taiwan
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY EXCIPIENT TYPE

  • 5.1. Introduction
  • 5.2. Polymers
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Alcohols
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness
  • 5.4. Sugars
    • 5.4.1. Market Opportunities and Trends
    • 5.4.2. Growth Prospects
    • 5.4.3. Geographic Lucrativeness
  • 5.5. Minerals
    • 5.5.1. Market Opportunities and Trends
    • 5.5.2. Growth Prospects
    • 5.5.3. Geographic Lucrativeness
  • 5.6. Others
    • 5.6.1. Market Opportunities and Trends
    • 5.6.2. Growth Prospects
    • 5.6.3. Geographic Lucrativeness

6. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FORMULATION TYPE

  • 6.1. Introduction
  • 6.2. Oral
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Topical
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Parenteral
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Others
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness

7. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY FUNCTIONALITY

  • 7.1. Introduction
  • 7.2. Coating Agents
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Flavoring Agents & Sweeteners
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Lubricants & Glidants
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Colorants
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness
  • 7.6. Emulsifying Agents
    • 7.6.1. Market Opportunities and Trends
    • 7.6.2. Growth Prospects
    • 7.6.3. Geographic Lucrativeness
  • 7.7. Buffering Agents
    • 7.7.1. Market Opportunities and Trends
    • 7.7.2. Growth Prospects
    • 7.7.3. Geographic Lucrativeness
  • 7.8. Others
    • 7.8.1. Market Opportunities and Trends
    • 7.8.2. Growth Prospects
    • 7.8.3. Geographic Lucrativeness

8. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY DISTRIBUTION CHANNEL

  • 8.1. Introduction
  • 8.2. Online
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Offline
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness

9. GLOBAL PHARMACEUTICAL EXCIPIENTS MARKET BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Excipient Type
    • 9.2.2. By Formulation Type
    • 9.2.3. By Functionality
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Excipient Type
    • 9.3.2. By Formulation Type
    • 9.3.3. By Functionality
    • 9.3.4. By Distribution Channel
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Excipient Type
    • 9.4.2. By Formulation Type
    • 9.4.3. By Functionality
    • 9.4.4. By Distribution Channel
    • 9.4.5. By Country
      • 9.4.5.1. Germany
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. France
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. UK
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. Italy
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Spain
        • 9.4.5.5.1. Market Opportunities and Trends
        • 9.4.5.5.2. Growth Prospects
      • 9.4.5.6. Others
        • 9.4.5.6.1. Market Opportunities and Trends
        • 9.4.5.6.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Excipient Type
    • 9.5.2. By Formulation Type
    • 9.5.3. By Functionality
    • 9.5.4. By Distribution Channel
    • 9.5.5. By Country
      • 9.5.5.1. Saudi Arabia
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. UAE
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Israel
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
      • 9.5.5.4. Others
        • 9.5.5.4.1. Market Opportunities and Trends
        • 9.5.5.4.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Excipient Type
    • 9.6.2. By Formulation Type
    • 9.6.3. By Functionality
    • 9.6.4. By Distribution Channel
    • 9.6.5. By Country
      • 9.6.5.1. China
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. Australia
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. Japan
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. India
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Taiwan
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Indonesia
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects
      • 9.6.5.9. Others
        • 9.6.5.9.1. Market Opportunities and Trends
        • 9.6.5.9.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. Ashland Global Holdings
  • 11.2. DuPont
  • 11.3. BASF SE
  • 11.4. Roquette Feres
  • 11.5. Evonik Industries AG
  • 11.6. Croda International
  • 11.7. Associated British Foods
  • 11.8. Archer Daniels Midland Company
  • 11.9. Lubrizol Corporation